BioVie Inc. (NASDAQ:BIVI) Short Interest Up 27.2% in January

BioVie Inc. (NASDAQ:BIVI) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 194,765 shares, an increase of 27.2% from the January 15th total of 153,081 shares. Based on an average trading volume of 92,484 shares, the short-interest ratio is currently 2.1 days. Approximately 2.6% of the company’s stock are sold short. Approximately 2.6% of the company’s stock are sold short. Based on an average trading volume of 92,484 shares, the short-interest ratio is currently 2.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioVie in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

BioVie Price Performance

Shares of NASDAQ:BIVI opened at $1.28 on Wednesday. The company has a market cap of $9.65 million, a P/E ratio of -0.39 and a beta of 0.56. BioVie has a 1 year low of $1.06 and a 1 year high of $18.60. The stock’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.62.

BioVie (NASDAQ:BIVI) last released its quarterly earnings data on Friday, February 6th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.04.

Hedge Funds Weigh In On BioVie

Several hedge funds and other institutional investors have recently modified their holdings of the company. DRW Securities LLC bought a new stake in shares of BioVie in the fourth quarter worth $149,000. Prosperity Wealth Management Inc. purchased a new position in BioVie in the third quarter worth about $273,000. Prelude Capital Management LLC bought a new stake in shares of BioVie during the 3rd quarter valued at about $275,000. Citadel Advisors LLC purchased a new stake in shares of BioVie during the 3rd quarter valued at about $199,000. Finally, Two Sigma Investments LP purchased a new stake in shares of BioVie during the 3rd quarter valued at about $62,000. 4.59% of the stock is owned by institutional investors.

About BioVie

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.